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Infection of Spodoptera frugiperda Sf9 insect cells 
with recombinant human androgen  receptor (AR) bac- 
ulovirus  results  in  expression of a 118-kDa phospho- 
protein that displays high affinity  androgen  binding 
and androgen-dependent targeting to the nucleus. 
Using the DNA mobility shift  assay, specific in vitro 
binding of full-length AR to androgen response element 
DNA (ARE) requires  intracellular hormone exposure. 
The ability of a variety of steroids to induce ARE 
binding  paralleled their  transcriptional potential. Cer- 
tain antihormones,  cyproterone  acetate and RU486, 
promote ARE binding, but a pure antiandrogen,  hy- 
droxyflutamide,  inhibits AR binding to ARE  DNA.  AR 
dimerization  requires  incubation of recombinant bac- 
ulovirus-infected insect cells  with  androgen,  but only 
when one or both components of the dimer  contain the 
NHderminal domain. Based on the intensities of  ARE 
binding and lack of binding to an ARE half-site, it 
appears  that,  unlike  the glucocorticoid receptor, AR 
binds DNA primarily as a dimer. Thus, full-length 
baculovirus-expressed AR requires  intracellular  hor- 
mone exposure for dimerization and ARE binding to 
overcome inhibition imposed by the AR NH2-terminal 
domain. Antihormones with  agonist  activity promote 
dimerization and ARE binding, while a pure  antian- 
drogen blocks AR DNA binding. It is concluded that 
intramolecular  interactions  between the  NHderminal 
and steroid-binding domains are regulated by the spec- 
ificity of hormone binding and modulate receptor  di- 
merization and DNA binding. 
The requirement for sufficient amounts of steroid receptors 
for structure/function studies and in vitro transcriptional 
analysis led to  the application of the baculovirus system for 
overexpression of recombinant receptors. Overexpression of 
the glucocorticoid (1,2), mineralocorticoid (31, vitamin D (4), 
progesterone (5,6),  and androgen (7,B) receptors was  achieved 
using bacdovirus. Expression in baculovirus is advantageous 
because of the potential for protein processing that occurs in 
eukaryotic cells. For example, phosphorylation of several ste- 
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roid receptors was  shown to occur in Spodoptera frugiperda 
(Sf9)l cells infected with recombinant baculoviral vectors (2, 
3,5),  and  the expressed receptors were functional in  transcrip- 
tional activation studies in vitro (6). Since transient transfec- 
tion in monkey kidney COS cells yields androgen receptor 
(AR) in a predominantly insoluble  form in limited amounts, 
baculovirus was  used for overexpression of human AR. 
An important question that remains in the functional 
analysis of  AR is whether dimer formation requires hormone 
binding and occurs in association with DNA binding. Many 
transcription factors, including members of the steroid recep- 
tor family,  undergo dimer formation in acquiring high affinity 
DNA binding (9). Dimerization of steroid receptors was dem- 
onstrated in the mobility shift assay using wild type and 
truncated forms of the progesterone, glucocorticoid (IO), and 
estrogen (11) receptors. Heterodimers were reported for the 
thyroid hormone, retinoic acid (12-14), and vitamin D recep- 
tors. The vitamin D receptor forms heterodimers with a 
ubiquitous 55-kDa protein that enhances DNA binding (15, 
16). Heterodimer formation with coregulatory proteins stabi- 
lizes  specific DNA interactions of this group of transcriptional 
regulatory proteins (14). 
Studies outlined in  this report demonstrate that AR ex- 
pressed in baculovirus displays high affinity androgen bind- 
ing, androgen-dependent nuclear translocation, and phos- 
phorylation. Mobility shift assays indicate that full-length 
baculovirus expressed AR requires intracellular androgen ex- 
posure to effect dimer formation and specific DNA binding. 
A surprising finding was that AR dimerization required an- 
drogen exposure in cells only  when the NHz-terminal domain 
was present. The results indicate that  the NH2-terminal do- 
main acts to inhibit AR dimerization and DNA binding in  the 
unliganded receptor. Furthermore, a pure antiandrogen, hy- 
droxyflutamide, lacks agonist activity because it inhibits AR 
The abbreviations used are: Sf9, Spodoptera frugiperda, AR, an- 
drogen receptor; AcMNPV, Autographa californica nuclear polyhed- 
rosis virus; R1881, methyltrienolone; PCR, polymerase chain reac- 
tion; ARE, androgen response element; flutamide, a-a-a-trifluor0-2- 
methyl-4‘-nitro-m-propionotoluidide, or 4’-nitro-3’-trifluoromethy- 
lisobutyranilide or SCH 13521; hydroxyflutamide, a-a-a-trifluoro-2- 
methyl-4’-nitro-m-lactotoluidide or SCH 16423; cyproterone acetate, 
6~-chloro-17a-hydroxy-la,2~-methylene-4,6-pregnadiene-3,20- 
dione-17-acetate; RU486, Roussel Uclaf list no.  36,486, mifepristone, 
11B-(4-dimethylaminophenyl)-17B-hydroxy-l7a-(prop-l-ynyl)-es- 
tra-4,9-diene-3-one; DHT, 5a-dihydrotestosterone, 17B-hydroxy-5a- 
androstan-3-one; AR1-660 or N, expressed fragment of human AR 
containing amino acids 1-660;  AR507-919 or C, expressed fragment 
of human AR containing amino acids 507-919;  m.o.i., multiplicity of 
infection; kb, kilobase(s); cpm, counts/min; PBS, phosphate-buffered 
saline; bp, base pair(s). 
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DNA binding, and thus, represents a new class of antihor- 
mones. 
EXPERIMENTAL PROCEDURES 
Materials-Spodoptera frugipenla Sf9 cells derived from the Fall 
Army  worm ovary, Trichoplusiu ni HighFiveW insect cells from cab- 
bage looper eggs, circular baculovirus Autograph californica nuclear 
polyhedrosis virus (AcMNPV, 130 kb), and transfection buffer were 
from Invitrogen Corporation, San Diego  CA,  pAcC4 baculovirus 
transfer vector was from Cetus Corp.; Grace medium supplemented 
with yeastolate (Difco) and lactalbumin hydrolysate (Difco), antibi- 
otics and gentamicin (Life Technology, Inc.)  were from the Lineberger 
Cancer Center, University of North Carolina at Chapel Hill; fetal calf 
serum was from HyClone Laboratories, Inc.; Trans36-label (L-["S] 
methionine, L-["Slcysteine),  1000 Ci/mmol was from ICN Biomedi- 
cals, Inc; phosphate-free and methionine-free, glutamine-supple- 
mented Excell  401 or 400 media were from JRH Biosciences; phos- 
phorus 32-orthophosphoric acid was from Du Pont; ['Hlmethyltrien- 
olone ([17~~-methyl-~H]R1881, SO Ci/mmol) was from Du Pont-New 
England Nuclear; W-0 MAT-AR diagnostic x-ray film was from 
Kodak; Taq DNA polymerase was from Promega; Sequenase was 
from U. S. Biochemicals; 0.025-pm cellulose membranes for dialysis 
was from Millipore; buffers, chemicals, and protease inhibitors were 
from were Sigma, Fisher, and EM Science. 
Construction of Transfer Vectors-Full-length and deletion mu- 
tants of human AR were constructed in  the 9.1-kb  pAcC4 transfer 
vector. Polymerase chain reaction (PCR) amplification of the human 
NcoIIAflII NHz-terminal fragment was constructed using Taq polym- 
erase such that  the 5' NcoI site contained the  starting Met of AR 
coincident in position with the  starting Met of the polyhedron protein. 
All PCR-amplified regions were  verified by sequence analysis using 
double-stranded sequencing with Sequenase. Triple ligations were 
performed using the transfer vector restricted with NcoI and  BamHI, 
the NH2-terminal PCR-amplified NcoIIAflII fragments, and the 
AflIIlBamHI fragments containing the AR coding sequence. For 
dimerization studies, two major deletion mutants of human AR  were 
constructed in the pAcC4 transfer vector. Deletion of the steroid- 
binding domain was achieved by restricting the full-length human 
AR transfer vector with Tthll lI   and XbaI to release the steroid- 
binding domain; the vector was made blunt ended with T4 DNA 
polymerase and self-ligated Deletion of the NHz-terminal domain 
was performed by restricting the full-length human AR transfer 
vector with NcoI and KpnI and blunt end-ligated; initiation of trans- 
lation was from an internal methionine at position 507 (17). 
Sfs CeU Cutture and Transfection"Sf9 cells were maintained in 
60-100-ml spinner  cultures in Grace medium containing 0.33% yeas- 
tolate, 0.33% lactalbumin hydrolysate, 10% fetal calf serum, 100 
units/ml penicillin, 100 pg/ml streptomycin, and 70 pg/ml gentami- 
cin, and were passaged every 3 days at an initial density of 0.5 X 10' 
cells/ml. Sf9 cells (4 X 10' cells/6-cm dish) were cotransfected with 
1 pg of circular AcMNPV wild type viral DNA and 5 pg  of  AR transfer 
vector using 0.75 ml of Invitrogen transfection buffer in  the presence 
of Grace medium that contained 10% serum but lacked supplements. 
After a 4-h incubation at 27 "C, medium  was  removed and  the cells 
were incubated in complete Grace medium for 5 days. The transfec- 
tion supernatants were subjected to serial dilution in 96-well micro- 
titer plates  containing 2 X lo' Sf9 cells/well, and recombinant viruses 
were identified by dot-blot hybridization as previously described (18). 
The radiolabeled probe was an  [aS2P]dCTP random prime labeled 
HindIII/EcoRI DNA fragment of human AR that spans the DNA- 
binding domain and part of the steroid-binding domain. Three rounds 
of serial dilution of positive samples were followed  by three rounds 
of plaque purification, where recombinant plaques were visualized 
using the methyl red overlay technique (19). 
Phosphorylation of Baculovirus-expressed AR-Sf9 cells were in- 
fected with recombinant human AR baculovirus at a multiplicity of 
infection (m.0.i.)  of 4 using 10' cells/lO-cm dish for 40-48  h. Medium 
was replaced with Excell 401 containing L-glutamine but lacking 
phosphate or L-methionine. After a 20-min incubation at 27  'C,  200 
pci of [8zP]orthophosphate or 200 pCi of Trans%-label was added 
and incubated for 4 h at 27  "C. Cells were harvested in 4 "C PBS, pH 
6.4, microfuged for 30 s, and resuspended in 800 pl of a buffer 
containing 1 mM EGTA, 1 mM EDTA,  12 mM monothioglycerol, 0.5 
M NaCl, 50 mM NaF, 1 mM benuunidine, 1 mM iodoacetamide, 20 
mM sodium molybdate, 100 nM R1881,0.5 mM phenylmethylsulfonyl 
fluoride, 1 pM leupeptin, 1 pM pepstatin, and 50 mM potassium 
phosphate buffer, pH 7.0. Cells were lysed using three cycles of freeze/ 
thaw and AR immunoprecipitated using antipeptide antibody AR52 
and analyzed on an 8% SDS-polyacrylamide gel as previously de- 
scribed (20). 
Immunoblot Analysis-In a control experiment, AR expressed from 
Sf9 cells was analyzed on immunoblots. Sf9 cells were plated at lo' 
cells/lO-cm dish, infected with recombinant virus for 40-48 h at m.0.i. 
4, and treated for varying times with increasing concentrations of 
dihydrotestosterone. Cells were washed and harvested in PBS, pH 
6.4, at 4 "C, pelleted, and resuspended in high salt extraction buffer 
(0.5 M NaC1,l mM EDTA, 1 mM dithiothreitol, 10% glycerol, 10 mM 
Tris, pH 7.4, containing the protease inhibitors, 0.5 mM phenylmeth- 
ylsulfonyl fluoride, 0.1 p~ aprotinin, 1 pM leupeptin, 1 pM pepstatin 
A, and 1 mM benzamidine). Cells were exposed to three cycles of 
freeze/thaw, incubated on ice for 1 h, microfuged for 30 min, and the 
supernatant dialyzed against the above resuspension buffer contain- 
ing 50 mM KCI. The dialyzed supernatant  and  the pellet were solu- 
bilized in SDS sample buffer (2% SDS, 10% glycerol, 10 mM Tris, 
pH 6.8) and analyzed on  an 8% acrylamide minigel. Immunoblots 
were performed using antipeptide antibody AR52 as previously de- 
scribed (21). 
Zmmunaytochemistry-Sf9 or HighFivee insect cells were infected 
with recombinant AR baculovirus at m.0.i. 4 in serum free Excell 400 
media for 40 h at 27 "C in  the presence or absence of 100 nM R1881. 
Cells were  washed in  PBS,  pH 6.4, and harvested in the same buffer. 
Cells were smeared on glass slides, air dried, and fixed in 95%  alcohol 
at -20 "C for 10 min. After washing with PBS, pH 7.4, cells were 
incubated with primary antibody AR32 overnight as previously de- 
scribed (22-24). After incubation, cells were treated with fluorescein 
isothiocyanate-conjugated goat anti-rabbit IgG (1:400; Organon Tech- 
nika, Cochranville, PA) for 1 h at room temperature. Slides were 
washed with PBS, pH 7.4, and mounted using 90%  glycerol, 1 mM 
Tris, pH 7.6, and a cover  glass placed on the cells. Slides were  viewed 
using a Nikon-UFX-DA fluorescent microscope with a B-2A filter. 
Steroid Binding Activity-Steroid binding was performed on intact 
Sf9 cells infected with human AR recombinant baculovirus using 
concentrations of ['H]R1881 ranging from 0.1 to 20  nM in the 
presence and absence of a 100-fold excess of unlabeled hormone. Cells 
were infected for 48 h at m.0.i.  2, incubated in Excell 400  media for 2 
h at 27 "C, and  then  as a whole  cell suspension in Excell 400 medium 
overnight at 4 "C.  Specific binding of [3H]R1881 was undetectable in 
uninfected cells or larvae. Nonspecific binding of ['H]R1881 ranged 
from 1-11% of specific binding for 5 and 0.2  nM, respectively. 
Gel  Mobility Shift DNA Binding Assay-DNA binding was assessed 
in vitro using recombinant full-length or deletion mutant human AR 
baculovirus expressed in Sf9 cells at m.0.i. 4 in the presence and 
absence of androgen or various hormones and antihormones. After 
48 h of viral infection, cells were incubated an additional 3 h or 
throughout the entire 48-h infection period at 27 "C with various 
hormones. Cells were harvested in ice-cold PBS, pH 6.4, and resus- 
pended in TEDG buffer (0.5 M NaCl, 1 mM EDTA, 1 mM dithiothre- 
itol, 10% glycerol, 10 mM Tris, pH 7.4, and protease inhibitors 
indicated above). Cells were  lysed  by three cycles of freeze/thaw and 
incubated on ice for 1 h with vortexing every 15 min. Cell lysates 
were microfuged for 30 min at 4 "C, and the supernatants were 
dialyzed  for 3 h at 4 "C on a floating 0.025-pm pore, MF-Millipore 
cellulose membrane filter against  TEDG buffer containing 50 mM 
KC1 to reduce the salt concentration, and microfuged for 1 min. 
A 27-bp oligonucleotide (AAGCTl'AGTACGTGATGTTCTAA- 
GCTT) designated oligonucleotide C h a s i i c e  derived from the 
0.5-kb first intron region of the rat C3 prostatein gene (25). The 
underlined regions highlight the androgen response element sequence. 
In a control study for monomer binding, a 21-bp oligonucleotide 
(TCGACTGACTCAATTG"G) with flanking SalI sites was used 
that contained only the right half-site (underlined) of the ARE 
sequence, shown previously to be the high affinity site for the gluco- 
corticoid receptor (26). Double-stranded oligonucleotides were labeled 
using [a-3ZP]dCTP  and  the Klenow fragment of DNA  polymerase. 
The reaction buffer containing 4 pg of poly(dI-dC), 80 pg  of bovine 
serum albumin, 15-30  pg  of infected Sf9 whole cell-extraded  protein, 
40 mM KCl, 20%  glycerol, 0.2 mM EDTA, 2 mM dithiothreitol, and 
10 mM Tris, pH 7.5, in a total volume of  20 pl,  was preincubated for 
15 min on ice. Labeled oligonucleotides (0.2-0.3 ng, 10,ooO or 20,000 
cpm) were added and incubated for 1 h on ice. The samples were 
incubated an additional 1 h in  the absence or presence of 1 pg of 
antipeptide antibody AR52 as previously described (24). For mobility 
shift assays to demonstrate AR dimerization, the amounts of cell 
extracts ranged from 20-30 pg where half  was either the full-length 
or deletion mutant AR extract. Samples were subjected to electro- 
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phoresis  on  nondenaturing 4 or 5% acrylamide  gels  containing 0.5 X 
TBE  (0.1 mM EDTA, 45 mM boric acid, and 45 mM Tris, pH 8.4). 
Gels  were  preelectrophoresed at 100 V for 1 h and  samples  separated 
at 150 V at 4 “C for 4-5 h or  for 260 V for 2 h (25,27, 28).  Gels were 
dried  under  vacuum  and  autoradiographed  by  exposure to Kodak X- 
OMAT  film at -7OC for  24-48  h. 
RESULTS 
Construction of Full-length and Truncated Human AR Re- 
combinunt Baculouiruses-The full-length coding sequence of 
human AR was cloned into  the NcoI and  BamHI  sites of the 
polylinker region of pAcC4 baculovirus transfer vector (Ce- 
tus). Cloning was achieved by ligation of the restricted vector 
with a 517-bp PCR amplified NHz-terminal NcoI/AflII AR 
fragment and a 2.24-kb AflIIIBamHI AR fragment  from the 
mammalian expression vectors pCMVhAR (29). As shown in 
Fig. lA, the vector contains sequences required for homolo- 
gous recombination with the wild type nuclear polyhedrosis 
virus from A. californica, AcMNPV, and a multiple cloning 
site that allows placement of the starting AR methionine 
coincident  with that of the polyhedron protein. Two major 
deletion mutants of human AR were also constructed (see 
“Experimental Procedures”) such that  the coding sequence 
contained the NHz-terminal and DNA-binding domains 
(amino  acids 1-660, designated AR1-660) or the DNA-bind- 
ing, hinge, and steroid-binding domains (amino acids 507- 
919, designated AR507-919) of the 919-amino-acid human 
AR. Sf9 insect cells were cotransfected with the transfer 
vectors and wild type AcMNPV DNA. Viral stocks were 
collected from infected cells and recombinant plaques en- 
riched by serial  dilution and dot-blot hybridization. Recom- 
binant plaque purification was achieved by visual screening 
for absence of polyhedrin-containing occlusion particles. Sev- 
eral plaques for each  construction were selected for further 
characterization. 
Properties of Baculouirus-expressed AR from Sf9 Cells- 
Cultured Sf9 cells maximally express AR within 30-48-h post 
infection at  m.0.i. 2-10 and produce a 118 f 4-kDa  protein 
that comigrates on an immunoblot  with AR expressed in COS 
cells (see Fig. 6). AR displayed high affinity, saturable binding 
of [‘H]R1881 in a whole cell binding assay, with approxi- 
mately 6 pmol/mg protein, and  the  apparent binding  affinity 
constant, Kd 0.3 k 0.2 nM (Fig. 1, B and C). A Hill coefficient 
of 1.2 suggested minimal cooperative androgen binding. 
AR undergoes androgen-dependent  translocation  from the 
cytoplasm to the nucleus in insect cells (Fig. 2). No fluorescent 
immunostaining was detected in uninfected Sf9 (Fig. 2A) or 
T. ni cells (Fig. 2 0 )  in agreement  with the lack of endogenous 
AR. In  the presence of 50 nM R1881, AR staining was pre- 
dominantly  nuclear (Fig. 2, B and E ) ,  particularly  within the 
virogenic stroma, a region of condensed chromatin within 
insect cell nuclei. AR distributed in  the cytoplasm of insect 
cells in the absence of androgen (Fig. 2, C and F). Thus, 
baculovirus-expressed AR undergoes androgen-dependent 
targeting  to  the nucleus in insect cells. 
AR phosphorylation was evident when baculovirus-infected 
Sf9 cells were incubated  with  [32P]orthophosphate. Androgen 
caused an increase in both receptor phosphorylation and 
stabilization  during a 3-h  incubation at  27 “C similar to  that 
previously reported for receptor expressed in COS cells (20), 
indicating that AR undergoes post-translation modification 
in insect cells and is a phosphoprotein (data  not shown). 
Intracellular Hormone Dependence of in Vitro AR DNA 
Binding-The intracellular  androgen dependence of specific 
AR DNA binding was determined in  an  in vitro DNA binding 
assay using a 32P-labeled 27-bp oligonucleotide containing a 
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FIG. 1. Recombinant baculovirus transfer vector and bind- 
ing studies. A,  Schematic  diagram of the AR baculovirus  transfer 
vector.  The  pAcC4 transfer vector from  Cetus  Corporation  contained 
sequences for homologous  recombination  with the nuclear  polyhed- 
rosis wild type AcMNPV baculovirus and a multiple cloning site 
following the polyhedrin  promoter. An  NcoI site  was  coincident  with 
the  starting Met of the polyhedrin  protein.  Full-length  human AR 
2.8-kb  coding  sequence was cloned into  the NcoI/BarnHI site in the 
polylinker  region.  The 5’ end of the human AR was constructed by 
PCR  amplification  using a 5’ primer  containing  the  NcoI site and the 
5’ coding  sequence of AR and  the 3’ primer  position 3’ of the  internal 
Am1 site. A triple  ligation led to  the final construct of 11.9 kb. B and 
C, saturation binding and Scatchard plot analysis of baculovirus 
expressed  human AR binding of  [‘H]R1881 in Sf9 cells. Sf9 cells  were 
infected with recombinant human AR baculovirus at m.0.i. 2 as 
described under “Experimental Procedures.” Cells were harvested, 
washed  in  PBS,  pH 6.4, and  aliquoted at approximately 2 X 10‘ cells/ 
assay. Intact cells  were  incubated at increasing  concentrations of [3H] 
R1881 in the presence  or  absence of unlabeled  R1881  overnight at 
4 “C, washed  three  times  in  PBS,  pH  6.4,  the  pellet  solubilized  in 2% 
SDS, 10% glycerol,  and  10 mM Tris, pH  6.8,  and  radioactivity deter- 
mined by scintillation counting. Specific binding represented the 
difference  between  counts/min  bound in the presence  and  absence of 
unlabeled hormone. Illustrated is total (O), nonspecific (m), and 
specific  binding (A) ( B )  and a Scatchard  plot of specific  binding (C). 
Apparent  binding constant Kd 0.3 k 0.2 nM Kd; Hill  coefficient 1.2. 
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FIG. 2. Immunofluorescent localization of human AR in Sf9 
and high five cells infected with recombinant human AR 
baculovirus. Sf9 cells and T. ni HighFive” cells were infected with 
recombinant human AR baculovims as described under  “Experimen- 
t a l  Procedures.” Immunofluorescent staining was performed using 
rabbit antipeptide IgG AR32 specific for AR. Immunostaining is 
shown for uninfected Sf9 cells ( A ) ,  Sf9 cells infected with recombi- 
nant human AR baculovims incubated in the presence ( B )  or absence 
(C) of 100 nM R1881; T. ni high five cells uninfected ( D ) ,  or infected 
with recombinant human AR baculovirus incubated in  the presence 
( E )  or absence (E’) of 100 nM R1881. Magnification X 500. 
nonspecific band was  observed when extracts from uninfected 
Sf9 cells were combined with ARE DNA, a protein-DNA 
complex that was unaffected by  AR antibody addition (Fig. 3, 
lanes 1 and 2). No additional DNA complexes were observed 
using extracts from cells infected with recombinant AR bac- 
ulovirus in the absence of androgen (Fig. 3, lane 13). However, 
addition of dihydrotestosterone to cells expressing AR re- 
sulted  in a dose-dependent formation of an AR - DNA  complex 
that increased in intensity as the concentration increased 
from 10 to 50 nM dihydrotestosterone (Fig.  3, lanes 3,5, 7, 9, 
and 11 ). The most intense  band observed in  the absence of 
antibody occurred following 24-48 h of treatment with 50 nM 
dihydrotestosterone (Fig. 3, lane 14). Unlabeled ARE DNA 
in 100-fold  excess competed for AR. DNA  complex formation 
(data  not shown) indicating that  the DNA binding was spe- 
cific. 
Dose-dependent androgen-induced increases in AR. DNA 
complex formation were also evident in the presence of the 
AR antipeptide antibody AR52. In  the absence of cell exposure 
to dihydrotestosterone, only weak intensity  bands were ob- 
served with full-length AR when tested with AR52 IgG at 
increasing concentrations of Sf9 cell extracts (Fig. 3, lanes 
c AR-AB-DNA 
+ AR-DNA 
AB52 - + ,- +I,- +I,- +I,- fl - - + + +I++fl 
DHT(nM) IO 20 40 50 50 -50- -- 50 
Hrs 3 3 3 1 3 4 8  48 
FIG. 3. Androgen dependence of baculovirus expressed hu- 
man AR binding to androgen response element DNA. Sf9 cells 
were uninfected with virus (lanes 1 and 2 )  or infected with the full- 
length human AR recombinant baculovirus (lanes 3-20) and incu- 
bated for varying times (Hrs)  with increasing amounts of DHT from 
10-50 nM as indicated. Cells were extracted in high salt containing 
buffer as described under  “Experimental Procedures” and 10 pg (lanes 
15 and 18), 15 pg (lanes 1-12), 20  pg (lanes 13,14,16, and 19), or 30 
pg (lanes 17 and 20) of whole cell extract was added to each 20 pl of 
binding reaction. Some reactions contained in addition 1 pg  of  AR52 
antipeptide IgG as indicated (+ AB52). The 32P-labeled androgen 
response element DNA (10,000 cpm/reaction) was added as described 
under “Experimental Procedures.” Two prominent bands were de- 
tected including the AR-androgen response element DNA  complex 
(AR-DNA) and that complexed with the AR antibody (AR-AB- 
DNA). The band at  the bottom of the gel represents unbound 32P- 
labeled ARE DNA. 
15-17). Addition of 50 nM dihydrotestosterone to  the Sf9 cell 
incubations 48 h prior to harvest and AR52  IgG to  the binding 
reactions caused up to a 120-fold increase in  band intensity 
(Fig.  3, lanes 18-20). A dose-dependent increase in complex 
formation with increasing androgen concentrations was  also 
observed in the presence of  AR antibody (Fig. 3, lanes 4,6,8, 
10, and 12). Addition of AR52 IgG potentiated androgen- 
dependent AR-DNA binding by at least 11-fold after cell 
incubation times of  1-3 h with androgen treatment. Enhance- 
ment of  AR DNA binding by antibody may reflect antibody 
stabilization of  AR dimerization (see below). Immunoblot 
analysis revealed similar amounts of AR protein in  extracts 
from  cells incubated in the absence and presence of increasing 
androgen concentrations for 3 h. After 30 h in the presence 
of androgen, some increase in AR protein was noted (data  not 
shown). 
Steroid Specificity of AR DNA Binding-We established 
whether exposure of Sf9 cells expressing AR to nonandrogenic 
hormones could effect AR DNA  binding. As shown in Fig. 4, 
hormone-induced ARE binding reflected the ability of that 
hormone to activate a reporter gene  previously reported (20). 
Strongest DNA binding was noted with the androgens, R1881, 
dihydrotestosterone, and testosterone (Fig. 4, lanes 1, 3, and 
5), and  the addition of  AR antibody further enhanced DNA 
binding (Fig.  4, lanes 2,4, and 6). Estrogen and progesterone 
promoted weak DNA binding only apparent  in  the presence 
of  AR antibody (Fig.  4, lanes 7-10). Weakest activities were 
noted with dexamethasone and flutamide which  do not bind 
AR with significant affinity at the concentrations tested. 
Somewhat to our surprise, the antiandrogen cyproterone ace- 
tate (Fig. 4, lanes 13 and 14) and  the antiprogestin RU486 
(Fig. 4, lanes 19 and 20) promoted relatively strong AR  DNA 
binding, particularly in the presence of antibody. Both of 
these  antihormones were  shown  previously to display agonist 
activity (20). 
Of particular interest was hydroxyflutamide, since it binds 
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FIG. 4. Steroid specificity of AR DNA binding. Sf9 cells ex- 
pressing AR  were incubated with 50 nM R1881 (lanes 1 and 21, DHT 
(lanes 3 and 4 ) ,  or testosterone (T,  lanes 5 and 6 ) ,  or 100 nM estradiol 
(E ,  lanes 7 and 8), progesterone (P, lanes 9 and I O ) ,  dexamethasone 
(Der, lanes 1 1  and 12), cyproterone acetate (CA, lanes 13 and 14), 
flutamide (FL, lanes 15 and 16), hydroxytlutamide (OH-FL, lanes 17 
and 18), or RU486 (lanes 19 and 20). Even numbered lanes had 1 pg 
of  AR52 antibody added during the DNA binding reactions. 
AB“,, - +   - +   - +  - +  
CONT DHT OH-FL DHT + 
OH-FL 
FIG. 5. Inhibition of androgen-induced  AR-DNA  binding  by 
hydroxyflutamide. Sf9 cells were left uninfected (lanes 1 and 2 )  or 
were infected with recombinant human AR baculovirus (lanes 3-8). 
Sf9 cells expressing AR were incubated for 42 h with 50 nM DHT 
(lanes 3 and 4 ) ,  100 nM hydroxytlutamide (OH-FL, lanes 5 and 6 ) ,  or 
simultaneously with 50 nM DHT  and 500 nM OH-FL (lanes 7 and 8 ) .  
Even numbered lanes contain cell extra- in which AR52 antibody 
(1 gg) was added during the DNA binding reaction (AB +). CONT, 
control uninfected cell extracts. 
AR with moderate affinity, causes nuclear transport,  but fails 
to transactivate an androgen-responsive reporter gene (20). 
Hydroxyflutamide was a poor activator of  AR DNA binding 
(Fig. 4, lanes 17 and 18). Furthermore, including hydroxyflu- 
tamide together with DHT in the cell incubations markedly 
reduced AR DNA binding (Fig.  5). These  results suggest that 
the antagonist activity of hydroxyflutamide results from its 
inability to invoke the necessary intracellular changes in AR 
to permit DNA binding. 
Receptor Dimerization-AR dimer formation was investi- 
gated using two deletion mutants of human AR expressed in 
baculovirus: AR1-660 contained the NHn-terminal and DNA- 
binding domains and AR507-919 contained the DNA-, hinge, 
and steroid-binding domains (diagrammed in Fig. 7). Expres- 
sion of the deletion mutants from baculovirus was  verified by 
immunoblot analysis, revealing truncated receptor forms of 
85 * 3 kDa (AR1-660, Fig. 6, lane 5, N )  and 43 f 1.5 kDa 
(AR507-919, Fig. 6, lane 6, C) relative to 118 k 4 kDa full- 
length AR (Fig. 6, lane 4). The smaller sized bands reflect 
limited proteolytic cleavage prior to analysis. Dimerization 
was examined using 32P-labeled ARE  DNA  described  above, 
and initially, receptors extracted from cells exposed to dihy- 
drotestosterone. 
Incubation of AR with ARE DNA resulted in a slowly 
migrating AR-DNA complex  (Fig. 7, lane 7). A faster migrat- 
ing complex  was  observed with AR507-919 (Fig. 7, lane 3), 
and AR1-660 formed a weak  DNA  complex migrating similar 
to full-length AR-DNA  (Fig.  7, lane 5 ) .  Addition of antipep- 
tide antibody AR52 caused a further shift in each band, 
verifying the presence of AR in the protein-DNA complexes 
(Fig. 7, lanes 4, 6, and 8). No  specific bands were  observed 
using extracts of uninfected cells in  the presence or absence 
of antibody (Fig. 7, lanes 1 and 2). 
AR dimerization was evident in  the mobility shift assay 
using combinations of truncated  and full-length receptors. A 
major band of intermediate migration formed  between  dele- 
tion  mutants AR1-660 and AR507-919 (Fig.  7, lanes 10-12). 
The intermediate band was  39- and 6-fold greater intensity 
than either  mutant alone, respectively,  suggesting a synergis- 
tic increase in DNA binding with dimerization. About 15% 
residual fragment AR507-919-DNA  complex migrated in its 
original position (Fig. 7, lane 12 compared with lane 11). 
Dimer formation between the dissimilar deletion mutants was 
therefore stronger than between either  mutant alone. 
Combining full-length AR and AR507-919 also resulted in 
strong dimer formation, with an intermediate band (Fig. 7, 
lanes 14-16) migrating slightly slower than the AR1-660- 
AR507-919 DNA  complex ( l a n e  12). Residual AR-DNA com- 
plexes remained detectable at their original positions of mi- 
gration. The ratio of intensity of the three bands was 2:7:1 
(Fig. 7, lane 16), corresponding to full-length AR, dimer, and 
AR507-919. Thus, dimerization between full-length AR and 
AR507-919 was preferred to dimerization of either with itself, 
assuming that AR. DNA  complexes  observed with each frag- 
ment alone represents dimerization (see below). 
Dimerization of full-length AR and AR1-660 results in 
inhibition of DNA binding of full-length AR (Fig. 7, lanes 18- 
20). The same low  level  of  DNA binding was  observed with 
full-length AR and AR1-660 as with AR1-660 alone, suggest- 
ing that, in the absence of one or both hormone-bound ligand- 
1 2 3 4 5 6  MW AR 
- 1 1 1  - 118 
- 72 - 85 
-45  - 43 
(kDa) 
COS - V WT N C 
F’IG. 6. Immunoblot analysis of full-length and  deletion  mu- 
tants  expressed from  baculovirus  in Sf9 cells. Cells plated at 
lO’/lO-cm dish were uninfected (lane 2) ,  or infected for 48 h with 
wild type virus lacking AR sequence (lane 3 ) ,  full-length human AR 
recombinant baculovirus (lane 4 ) ,  carboxyl-terminal deletion mutant 
AR1-660 (amino acids 1-660 lane 5, designated N ) ,  NH2-terminal 
deletion mutant AR507-919 (amino acids 507-919, lane 6, designated 
C). Cells  were harvested in PBS, pH 6.4, extracted in high salt buffer 
(0.5 M NaCl, 1 mM EDTA, 10% glycerol, 10 mM Tris, pH 7.4, 
containing 0.5 mM phenylmethylsulfonyl fluoride, 0.1 pM aprotinin, 
1 pM leupeptin, 1 p~ pepstatin A, 1 mM benzamidine) and subjected 
to three cycles of freeze/thaw. Aliquots were analyzed on immunoblots 
as described under  “Experimental Procedures.” Full-length AR from 
transiently  transfected COS cells (COS, lane 1 ) prepared as previously 
described (17) served as a positive control for full-length human AR. 
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FIG. 7. Dimerization  of  human  AR. Receptor  dimerization was 
determined  in the DNA mobility shift assay  using Sf9 cells  infected 
with  recombinant  baculovirus  encoding either full-length AR ( WT), 
AR1-660 (amino  acids 1-660, N )  or AR507-919 (amino  acids 507- 
919, C) as  indicated.  Dihydrotestosterone (50 nM)  was  added to the 
media at the time of transfection, 48 h prior to cell harvest and 
extraction. Whole cell extracts (20 pg total protein/reaction) were 
prepared as described under “Experimental Procedures” and incu- 
bated  in the DNA binding  assay  using  32P-labeled  androgen  response 
element DNA; reactions with different AR fragments  contained 10 
fig of protein from each cell extract. Sf9 cell extracts were from 
uninfected  cells (lanes 1,2,9, 13, and 17) or  from  cells infected  with 
the full-length AR (lanes 7,8,15,16,19, and 20), AR1-660 (lanes 5, 
6,10,12,18, and 20), and AR507-919 (lanes 3,4,11,12,14, and 16). 
The presence of AR in the DNA complex  was established by adding 
to some reactions 1 pg of AR52 IgG antibody (lanes 2,4, 6, and 8). 
Arrows highlight the major  DNA-protein  complexes in lanes 12 and 
16.  Below is a schematic  diagram illustrating regions of AR expressed 
by the wild type and mutant vectors. 
binding  domains,  the  two  NH2-terminal  domains  in  the  AR 
dimer  inhibit  DNA binding. 
Intracellular Androgen Dependence of in Vitro Dimeriza- 
tion-We next  determined  whether  androgen  exposure of Sf9 
cells expressing  AR  was  required for AR507-919 dimerization 
with itself or with  full-length AR. AR507-919 extracted  from 
cells untreated  with  androgen  produced a strong  migrating 
DNA-protein complex (Fig. 8, lane 3 )  which migrated  slightly 
faster  than  when  extracted  from  androgen  treated cells (Fig. 
8, lane 1 ). The  strong  band  intensities suggest that  AR507- 
919 is capable of binding DNA independent of androgen 
exposure  in Sf9 cells. The slight difference in  migration  may 
result  from  conformational  differences  in AR507-919 in  the 
presence or absence of androgen binding. Both AR507-919- 
DNA complexes shifted  with  antibody (Fig. 8, hnes 2 and 4 ) .  
Further evidence for  dimerization of  AR507-919 independ- 
ent of androgen was obtained  using an oligonucleotide con- 
taining a single right  half-site  ARE  consensus  sequence 
TGTTCT (see ”Experimental  Procedures”). A similar oligo- 
nucleotide  was  used previously to  demonstrate  monomer  bind- 
ing of the glucocorticoid receptor (30). Little or no  detectable 
bands were observed using  full-length AR507-919 with  the 
right half-site oligonucleotide (Fig. 9, lanes 6 and 8). In  a 
control experiment, full-length glucocorticoid receptor ex- 
pressed  from baculovirus  displayed binding to both  the  half- 
site  and full ARE (Fig. 9, lanes 3 and 4 ) .  Monomer  binding of 
the glucocorticoid receptor  was  also  evident by the  change  in 
mobility of DNA complexes formed  between the dissimilar 
oligonucleotides (Fig. 9, lanes 3 and 4) .  The results suggest 
that AR, either  in  its  full-length or NH2 terminally  truncated 
form, binds  DNA  primarily as a dimer  and  that  ARE  binding 
of AR507-919 reflects  dimer binding. Furthermore, AR507- 
919 dimerization and DNA binding occurs independent of 
androgen exposure. 
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FIG. 8. Requirement  for  intracellular  androgen  exposure  in 
AR dimerization. Dimerization was studied  in the DNA mobility 
shift assay using AR507-919 (C) and full-length AR (WT). Cells 
expressing AR507-919 or full-length AR were  incubated  in the pres- 
ence  or  absence of 50 nM dihydrotestosterone ( D H T )  as indicated 
+/+, C and WT treated with  hormone, -/+, only  WT treated with 
DHT, +/-, only C treated with DHT; -/-, neither treated with 
hormone.  Cell extracts were  combined  in the DNA binding  reaction 
as indicated in lanes 11,14,17, and 20 and assayed as described  under 
“Experimental  Procedures”  using the C3 ARE [32P]oligonucleotide. 
Lanes 2,4, 6, and 8 contained samples to which AR antibody AR52 
was  added ( A B  +). Below is a schematic  diagram of AR507-919 and 
full-length AR coding  regions. 
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FIG. 9. Absence  of AR monomer  binding to  a  right half-site 
ARE. Sf9 cells expressing full-length glucocorticoid receptor (GR, 
lanes 3 and 4), full-length AR (lanes 5 and 6), and AR507-919 (AR- 
C, lanes 7 and 8) were treated with  either  dexamethasone  for  gluco- 
corticoid  receptor  as  previously  described (1) or  with 50 nM R1881 
for 40 h.  High salt cell extracts prepared as described  under  “Exper- 
imental  Procedures” were incubated  in the presence of either 20,000 
cpm/reaction of the full ARE [32P]oligonucleotide (designated E, 
lanes 3, 5, and 7) or with 50,000 cpm/reaction [ 3 2 P ] ~ l i g ~ n ~ ~ l e ~ t i d e  
containing only the right half-site ARE (TGTTCT) (designated  1/2, 
lanes 4, 6, and 8). Full and half-site labeled oligonucleotides were 
assayed  in  addition  with Sf9 cell extracts without  prior  viral  infection 
(lanes 1 and 2) or with no protein addition to the DNA binding 
reaction (lanes 9 and 10). DNA binding assays were performed as 
described  under  “Experimental  Procedures,” and the reaction  mix- 
tures were separated on a 4% nondenaturing  agarose gel at 4 “C at 
170 V for 2 h. The band at the bottom of the gel represents  unbound 
32P-labeled DNA. CONT, control  uninfected  cell  extracts. 
Full-length AR dimerization  with AR507-919 was exam- 
ined  where  either  one or both were  exposed to androgen in 
Sf9 cells. As shown above, dimerization occurred when both 
full-length AR and AR507-919 were exposed to androgen 
(Fig. 8, lanes 9-11). However, if either was untreated  with 
androgen,  no  dimerization  was observed (Fig. 8, lanes 12-20). 
Thus,  unlike AR507-919 dimerization  with itself,  dimeriza- 
tion of full-length  AR  with AR507-919 required that each  be 
exposed to androgen in Sf9 cells. The results support the 
hypothesis that  the AR NHp-terminal domain  inhibits  dimer 
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formation in the absence of androgen and that androgen 
treatment relieves this inhibition. 
Since AR1-660 and AR507-919 form a strong dimer band 
(see Fig. 7, lane 12), it was important to establish whether 
AR507-919 in this complex required androgen exposure as  it 
did in dimerization with full-length AR but  not with itself. 
Fig. 10  shows that androgen exposure of AR507-919 in Sf9 
cells is required for dimerization with AR1-660. The results 
reaffirm the inhibitory influence of the NH2-terminal domain 
in dimer formation, even in  a complex where one fragment 
contains the steroid-binding domain and  the  other contains 
the NHn-terminal domain. The results raise the possibility 
that regions required for strong dimer formation are located 
within the domains of these dissimilar AR fragments. 
Finally, we tested the hormone specificity of dimerization. 
In control experiments in the absence of hormone, full-length 
AR fails to bind the ARE, AR507-919 binding is  strong  and 
dimerization between them  is undetectable (Fig. 11, lanes 2- 
4 ) .  Strong dimerization occurs with R1881 and  DHT (Fig. 11, 
lanes 5-10). Dimers are also detected with cyproterone acetate 
( l a n e  13) and RU486 ( l a n e  16), but DNA binding and dimer- 
ization fails to occur with hydroxyflutamide (lanes 17-19). It 
is noteworthy that  the migration of  AR507-919 changes mark- 
edly depending on hormone treatment.  For example, AR507- 
919 migration with dihydrotestosterone (Fig. 11, lane 9 )  dif- 
fers from that with R1881 ( l a n e  6) but is similar to that 
observed in the absence of hormone ( l a n e  3). Also, it is 
important to note that hydroxyflutamide inhibits ARE bind- 
ing of both full-length AR ( l a n e  17) and AR507-919 (compare 
lanes 3 and 18). The change in AR507-919 DNA complex 
migration likely reflects changes in receptor conformation 
resulting from hormone binding. 
DISCUSSION 
Overexpression of recombinant steroid receptors provides 
an important approach with which to determine the molecular 
properties of this family of transcriptional regulatory proteins. 
By the criteria of androgen binding, subcellular localization, 
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FIG. 10. Androgen dependence of AR dimerization using  the 
AR1-660 and AR607-919 deletion mutants. Sf9 cells express- 
ing AR1-660 ( N )  or AR507-919 (C) were incubated  in the presence 
(+) or absence (-) of 50 nM DHT  as  indicated +/+, both treated 
with  DHT; +/-, only AR1-660 treated with DHT. Cell extracts were 
combined in the DNA binding reaction as indicated in lanes 5 and 8. 
Lanes 9 and 10 contain extracts from cells infected with the wild type 
baculovirus. Cell extracts  in lanes 2 and 10 had AR52 antibody added 
in the DNA binding reaction (AB +). 
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FIG. 11. AR dimerization in the presence of androgens and 
encoding either full-length AR ( W T )  or AR507-919 (C) as indicated. 
antihormones. Sf9 cells were infected with recombinant baculovirus 
Cells were incubated with 50 nM R1881, 50 nM DHT, 100 nM 
cyproterone acetate (CA),  100 nM RU486, or 100 nM hydroxyflutam- 
ide (OH-FL) as indicated. Whole cells extracts (20 pg  of total protein/ 
reaction) were incubated with 32P-labeled ARE oligonucleotide in the 
DNA binding assay. Reactions containing two AR fragments con- 
tained 10 pg of total  protein from each cell extract  treated with or 
without hormone. Lane 1 contains control cell extract from Sf9 cells 
without  prior viral infection (CON). Lane 20 contains the 32P-labeled 
oligonucleotide to which no  protein was added in the DNA binding 
reaction. The radiolabeled band at  the bottom of the gel represents 
unbound labeled ARE DNA. 
and phosphorylation, a functional AR is expressed in Sf9 cells 
from baculovirus. It was determined that the AR requires 
prior intracellular exposure to androgen in order to acquire 
the ability to bind an ARE sequence in vitro. The steroid 
specificity of this hormone-dependent intracellular change in 
AR correlated with agonist activity demonstrated previously 
for a variety of hormones (20). Particularly noteworthy was 
the differential response of the antihormones: those that 
display agonist activity in transient cotransfection assays 
(cyproterone acetate  and RU486)  induce AR DNA binding, 
while the pure antiandrogen, hydroxyflutamide, which lacks 
agonist activity, failed to  potentiate AR DNA binding, and, 
in fact, inhibited AR DNA binding when added together with 
androgen. The antagonistic activity of hydroxyflutamide re- 
sults, therefore, from its failure to induce changes in AR 
necessary for DNA binding. 
To investigate further the molecular basis for the steroid- 
mediated changes in AR required for DNA binding, two AR 
deletion mutants were expressed from baculovirus in Sf9 cells. 
The results indicate that AR undergoes dimerization in as- 
sociation with ARE binding, and, as a monomer, fails to bind 
the ARE. Furthermore, by using different combinations of 
full-length and AR deletion mutants, it was established that 
dimerization was dependent on intracellular hormone expo- 
sure in order to overcome inhibition created by the AR  NH2- 
terminal domain. This conclusion was supported by the ob- 
servation that deletion mutant AR507-919, which  lacked the 
NH2-terminal region, dimerized and bound DNA efficiently 
in the absence of hormone, and that  the presence of the NH2- 
terminal domain blocked this hormone independent DNA 
binding. Finally, it is speculated that  the hormone specificity 
of DNA binding reflects the ability of a given hormone to 
promote conformational changes in AR that overcome NHZ- 
terminal domain inhibition. 
The critical role of hormone in steroid receptor action is 
believed to be activation of receptors to a DNA binding state. 
The demonstration of hormone-dependent DNA binding is 
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sometimes complicated by isolation procedures that often 
cause artificial receptor activation so that receptors no longer 
require hormone for high affinity DNA binding. Sf9 cells 
expressing AR must be exposed to androgen intracellularly in 
order to render the receptor capable of binding DNA in  vitro. 
In a recent study using baculovirus-expressed AR, binding to 
androgen response element DNA occurred independent of 
androgen exposure (7). An explanation for the differing re- 
sults is that  the AR used in  the previous report was extracted 
using denaturing conditions and was subsequently renatured. 
Ligand-dependent DNA binding was reported, however,  for 
baculovirus-expressed human progesterone receptor (5,6). 
Antihormones bind AR with moderate affinity, cause nu- 
clear transport (20), but, as shown in  this report, differ in 
their ability to induce DNA binding. These observations 
suggest that hormone binding may  impose different confor- 
mations on the receptor, which either allow or disallow DNA 
binding. That steroid hormones play a major  role in receptor 
conformation is supported by the recent study of Allan et al. 
(31) where proteolytic cleavage products differed in size after 
hormone and antihormone exposure of the progesterone 
receptor. It was  proposed that distinct receptor conformations 
are induced  by hormone and antihormone binding. The  pri- 
mary site for conformational modification was thought to be 
the carboxyl-terminal tail (32). A monoclonal antibody raised 
against the 14 terminal amino acids of the progesterone 
receptor only  recognized the progesterone receptor when un- 
liganded or bound to the steroid antagonist, RU486, suggest- 
ing that agonist binding induces a unique receptor confor- 
mation (33). Our studies using hydroxyflutamide support the 
formation of an improper receptor conformation that inter- 
feres with DNA  binding. This was evident even with the NH, 
terminally truncated  mutant AR507-919, that without hor- 
mone,  displayed strong DNA binding, but with hydroxyflu- 
tamide, showed inhibition of DNA binding. 
Further evidence for the importance of the carboxyl-ter- 
mind tail  in conformational effects that differentiate agonist 
and antagonist activity comes  from a switch in  the activity of 
hydroxyflutamide  from antagonist to agonist in an AR mu- 
tant. Agonist activity of hydroxyflutamide is undetectable 
with wild type AR but becomes significant with an AR mutant 
containing a single base mutation at amino acid residue  877, 
changing threonine to alanine, in  the carboxyl-terminal region 
of the AR steroid-binding domain (34,35). It could  be specu- 
lated that  the single residue change contributed to a change 
in AR conformation when  bound to hydroxyflutamide  which 
potentiated DNA binding and thus, transactivation. Simi- 
larly, a single amino acid change in the progesterone receptor 
disallowed antagonist RU486, but  not agonist binding (36). 
Alternative mechanisms for the molecular basis of steroid 
antagonism include reduced nuclear translocation with con- 
comitant inhibition of 10 S to 4 S conversion, as shown  for 
the glucocorticoid receptor (37). All  of the antihormones 
tested in the present report, including hydroxyflutamide, 
caused nuclear transport of  AR (20) and preliminary studies 
with baculovirus-extracted receptor indicate that hormone- 
and nonhormone-treated receptors migrate as 5-6 S com- 
plexes on sucrose gradients. Studies on RU486 interaction 
with the human progesterone receptor indicate that binding 
to a specific response element was indistinguishable from that 
with the synthetic agonist, R5020 (38). Although the proges- 
terone receptor binds its response element when associated 
with RU486, it apparently binds with a somewhat altered 
conformation reflected by differences in migration on sucrose 
gradients and  in DNA mobility shift assays; failure to  tran- 
sactivate results therefore from structural alterations (39). 
Using deletion mutants of the rabbit progesterone receptor, 
it was demonstrated that RU486-bound receptors interact 
with the same response element (40). In agreement with these 
studies, the AR-RU486 dimer appeared to migrate with 
slightly altered mobility. These studies support the important 
role  of receptor conformation mediated by steroid binding in 
transcriptional activation. They  point  out hat  the molecular 
basis of hydroxyflutamide antagonism differs from that of 
most antihormones reported thus  far, which bind with high 
affinity to their respective hormone response elements, as 
recently summarized (41, 42). Hydroxyflutamide therefore 
belongs to a new class of “pure” antagonists that lack agonist 
activity due to their inability to promote specific DNA bind- 
ing. 
AR dimerization and  the inhibitory role  played by the  NHz- 
terminal domain was  revealed  using full-length and deletion 
baculovirus expressed mutants in the DNA mobility shift 
assay. AR1-660, that contains the NH2-terminal and DNA- 
binding domains, and AR507-919, the DNA- and steroid- 
binding domains, showed strong hormone-dependent dimeri- 
zation. Thus, a major dimerization domain  may  reside within 
their overlapping regions in the DNA binding and hinge 
regions. Alternatively, dimerization may  involve distinct re- 
gions in each of the dimer components. The DNA-binding 
domain of the glucocorticoid receptor contains a dimerization 
region  (10, 11) within a so-called D box of the second  zinc 
finger (43,44). Crystal structure analysis of the glucocorticoid 
receptor DNA-binding domain was linked directly to DNA 
binding-induced dimerization (45). A major dimerization do- 
main of the estrogen receptor occurs within the steroid- 
binding domain (46), and the ligand-binding domain was 
proposed as a site for a major dimer interface that interacts 
with the same region in the dimer component (44). Such a 
mechanism does not comply with our results with AR. A 
dimerization region within the steroid-binding domain must 
necessarily interact with a region outside the steroid-binding 
domain in  the  other dimer component. 
The intensity of DNA-receptor complex formation between 
AR1-660 and AR507-919 deletion mutants exceeded that 
observed with AR1-660 and  the full-length receptor, both of 
which contain the NHz-terminal region. The results suggest 
that the AR NHz-terminal domain within the dimer weakens 
dimer strength. The results raise the possibility that efficient 
dimerization and DNA binding might occur  when AR heter- 
odimerizes  with another protein. In  this regard, it was recently 
reported that a truncated form of  AR expressed in Escherichia 
coli complexes with an AR accessory factor that potentiates 
DNA binding (47). 
After short incubation with androgen (1-3 h), AR displayed 
relatively weak  DNA binding that was potentiated by anti- 
body. AR antibody did not enhance DNA binding using  ex- 
tracts of cells untreated with androgen, even though the 
extraction buffer contained high salt. Furthermore, more pro- 
longed androgen exposure of Sf9 cells (48 h) caused AR to 
bind DNA strongly independent of antibody. It was noted 
that addition of androgen to the in  vitro DNA binding reaction 
without prior exposure of Sf3 cells  was  ineffective in promot- 
ing DNA binding, even though specific  high affinity androgen 
binding was measured. These results, taken together, indicate 
that intracellular changes occur in AR in  response to androgen 
that enable the receptor to bind DNA. The molecular basis 
for this sequential, time-dependent acquisition of DNA bind- 
ing remains to be determined. Post-translational modification 
of  AR such as phosphorylation occurs in Sf9 insect cells and 
could theoretically have a role  in the induction of strong DNA 
binding. Antibody may stabilize receptor dimerization or a 
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conformation conducive to DNA  binding. 
The results indicate that AR activation in Sf9 cells requires 
hormone- and time-dependent intracellular processes. Certain 
pure antiandrogens lack agonist activity because they fail to 
promote dimerization and DNA binding. Failure to promote 
DNA binding likely results from an altered conformation 
imposed  on the ligand-binding domain. The AR NH2-terminal 
domain blocks  DNA binding in the absence of the appropriate 
ligand by interfering with receptor dimerization. 
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